It is clear that large cohorts of subjects and prospective studies may produce more consistent and accurate data, resulting in superior value for ki67 as a specific tool in the management strategy of differentiated thyroid carcinoma, with clear indications and pertinent cutoff values, since, at present, these aspects are peculiar and not fully standardized. This evidence concerns the gene MKI67 and differentiated thyroid carcinoma.